Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05683379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Primary completion moved earlier from Sep 2026 to Jun 30, 2026 · Site details revisedv6 Show 2 more changesShow less
    • Primary completion moved earlier from Sep 2026 to Jun 30, 2026
    • Site details revised
  2. Site contact updatedv5
  3. Eligibility criteria revised Secondary endpoints shortened, about 8 words · Study description expanded, about 9 words · Study title revisedv4 Show 3 more changesShow less
    • Secondary endpoints shortened, about 8 words
    • Study description expanded, about 9 words
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Dec 2024 to Sep 2026 Site contact updatedv3 Show 1 more changeShow less
    • Site contact updated
  5. Site contact updatedv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Trial Details
NCT Number NCT05683379
Lead Sponsor REGENXBIO Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov